Helius Medical Technologies (Helius Medical Technologies) Sloan Ratio % : 20.74% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Helius Medical Technologies's Sloan Ratio for the quarter that ended in Dec. 2023 was 20.74%.

As of Dec. 2023, Helius Medical Technologies has a Sloan Ratio of 20.74%, indicating there is a warning stage of accrual build up.

Helius Medical Technologies Sloan Ratio % Historical Data

The historical data trend for Helius Medical Technologies's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helius Medical Technologies Sloan Ratio % Chart

Helius Medical Technologies Annual Data

Trend

Mar14

Mar15

Mar16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

Get a 7-Day Free Trial

115.85

-36.40

-33.24

1.44

20.74

Helius Medical Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sloan Ratio %	Get a 7-Day Free Trial															1.44	4.59	17.31	-24.19	20.74

Competitive Comparison of Helius Medical Technologies's Sloan Ratio %

For the Medical Devices subindustry, Helius Medical Technologies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helius Medical Technologies's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Helius Medical Technologies's Sloan Ratio % falls into.

Helius Medical Technologies Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Helius Medical Technologies's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-8.85	-	-10.416
	-	-0.029)	/	7.692
	=	20.74%

Helius Medical Technologies's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Dec. 2023 )
	=	(-8.85	-	-10.416
	-	-0.029)	/	7.692
	=	20.74%

Helius Medical Technologies's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -2.494 (Mar. 2023 ) + -1.648 (Jun. 2023 ) + -3.663 (Sep. 2023 ) + -1.045 (Dec. 2023 ) = $-8.85 Mil.
Helius Medical Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -3.19 (Mar. 2023 ) + -2.74 (Jun. 2023 ) + -2.452 (Sep. 2023 ) + -2.034 (Dec. 2023 ) = $-10.42 Mil.
Helius Medical Technologies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.019 (Mar. 2023 ) + -0.001 (Jun. 2023 ) + -0.006 (Sep. 2023 ) + -0.003 (Dec. 2023 ) = $-0.03 Mil.

Helius Medical Technologies (NAS:HSDT) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Helius Medical Technologies has a Sloan Ratio of 20.74%, indicating there is a warning stage of accrual build up.

Helius Medical Technologies Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Helius Medical Technologies (Helius Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (NAS:HSDT) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940

Website

https://www.heliusmedical.com

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Executives

Dane Andreeff	director, 10 percent owner, officer: President and CEO	C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459
Jeffrey S Mathiesen	director, officer: CFO and Treasurer	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Favit-van Pelt Antonella R.	officer: Chief Medical Officer	C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Sherrie L Perkins	director	5033 TANGLE LANE, HOUSTON TX 77056
Jennifer Laux	officer: Chief Commercial Officer	642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940
Thomas E Griffin	director	C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Blane Walter	director	500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082
Edward M Straw	director	C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153
Joyce N Laviscount	officer: See Remarks	100 ENDO BOULEVARD, CHADDS FORD PA 19317
Huaizheng Peng	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Philippe Deschamps	director, 10 percent owner, officer: President & CEO	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Mitch E Tyler	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Jonathan Sackier	10 percent owner, officer: Chief Medical Officer	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
A&b (hk) Co Ltd	10 percent owner	8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057